Aphria (TSX:APHA) Is Fast Shaping Up to Be the Top Pot Stock to Own

Aphria Inc. (TSX:APHA)(NYSE:APHA) is an attractively valued play on the burgeoning global legal marijuana market.

Marijuana stocks have been roughly handled by the market since the start of 2019 with many pundits fearing that sales would not support their nose-bleed valuations. A spate of regulatory investigations and claims that the global legal cannabis market is not as big as initially claimed have only magnified those fears.

Leading cultivator Aphria (TSX:APHA)(NYSE:APHA), which was derided in a research report in late 2018, continues to demonstrate why it is one of the very few marijuana stocks to own.

Profitable grower

Unlike industry leader Canopy Growth, it has proven that it can be profitable in the difficult operating environment afflicting the industry. It was Canopy’s massive fiscal 2019 loss of $685 million which rattled markets and saw cannabis stocks heavily marked down.

The fears that triggered regarding cannabis stocks were further magnified by Canopy’s first-quarter fiscal 2020 $1.3 billion loss, which saw the company shed a whopping 41% over the last three months.

In comparison, Aphria reported a fiscal first-quarter profit of $16 million, and that came on the back of a full-year 2019 loss of $16.6 million, indicating that the cultivator is building sales momentum and starting to deliver value for shareholders.

A key reason for Aphria’s impressive performance compared to its peers is that it is among Canada’s lower-cost producers reporting first-quarter 2020 cash costs of $1.43 per gram of cannabis produced and $2.52 a gram for its all-in sustaining costs (AISCs). Those costs were higher than they had been a year earlier and that can be attributed to higher packaging, conversion, and distribution costs because of a significant 39% year-over-year increase in production.

Aphria was beset by a range of issues, which impacted its performance during the quarter, including a fire at Aphria’s Broken Coast facility, which prevented it from making shipments during the last 11 days of the quarter. As they are resolved by Aphria, its earnings and profitability should expand.

A key strength is that the company has developed a global cultivating footprint, which is expected to reach 2.4 million square feet in Canada alone once the Aphria Diamond facility is approved This will allow it to produce up to 255,000 kilograms in Canada annually.

In a positive development, the industry regulator Health Canada has indicated that it is expediting the licensing process for Aphria Diamond. That will allow the cultivator to boost its dried flower output and meet supply contracts, thereby further boosting earnings.

Another compelling reason to invest in Aphria is that it has established a large global distribution network, encompassing Canada, Western Europe, and Australia. This includes a significant presence in Germany, which is viewed as one of the most lucrative medical marijuana markets globally, although Aphria is experiencing issues in that market which forced it to adjust its strategy.

While some pundits point to the fact that Aphria receives most of its earnings from distribution operations rather than the sale of dried flower as being an issue, it is not as significant as some pundits believe. This points to the effectiveness of Aphria’s distribution network and the considerable value add that it adds to its cultivating operations.

Ultimately, it will be the strength of a legal marijuana company’s distribution network which will form a key part of its economic moat, because cannabis cultivation is a relatively easy business to enter.

As the U.S. increasingly legislates in favour of legal marijuana cropping and reduces industry barriers, more capital will become available, leading to a flood of new cultivators all fighting for a slice of the same limited market. That — along with Latin America’s rapidly expanding legal cannabis industry, where dried flower can be produced for less than a 10th of what it costs in Canada — means that the market will be flooded with growers.

Foolish takeaway

Aphria has been one of the few major Canadian legal cannabis cultivators to prove that it is profitable in what is essentially an untested global marijuana market. This, coupled with its steadily progressing plans to expand production capacity and large global distribution network, makes it a top play in the burgeoning global legal marijuana market.

Those characteristics also point to it being one of the very few cannabis cultivators to survive the looming rationalization of the industry.

Fool contributor Matt Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »